High concordance of TMPRSS-ERG fusion between primary prostate cancer and its lymph node metastases

Approximately 50% of prostate cancer types harbor the transmembrane protease, serine 2: Erythroblast transformation-specific-related gene (ERG) fusion, resulting in oncogenic expression of the ERG transcription factor. ERG represents an attractive target for potential future anticancer therapy in advanced and metastatic prostate cancer. To better understand whether the analysis of the primary cancer is sufficient to estimate the ERG expression status of the lymph node metastases, the present study examined patterns of immunohistochemical ERG expression in a tissue microarray created from multiple primary and metastatic sites of 77 prostate cancer tissues. Among the identified tumor types, 80% were either entirely ERG-positive (38%) or ERG-negative (42%) across all (at least 9) analyzed different tumor sites. The results were heterogeneous in 20% of the tumor types and typically resulted from small ERG-negative areas within otherwise ERG-positive tumor types. Comparison of the ERG expression status in 51 primary cancer types with at least three interpretable lymph node metastases revealed an entirely identical ERG status in all tumor sites in 75% of the cases, including 16 ERG-positive and 22 ERG-negative cancer types. The remaining 13 cancer types exhibited ERG heterogeneity within the primary tumor, while all metastases had an identical (12 positive and 1 negative) ERG status. The results of the present study revealed a high degree of concordance of the ERG expression status between primary prostate cancer types and their lymph node metastases. Therefore, potential anti-ERG therapy may also be effective against lymph node metastases in the majority of cases of ERG-positive metastatic prostate cancer.

[1]  N. Muhammad,et al.  Cancers , 2018, Examining the Causal Relationship Between Genes, Epigenetics, and Human Health.

[2]  S. Varambally,et al.  Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer. , 2017, Cancer cell.

[3]  J. Korbel,et al.  Heterogeneity of ERG expression in prostate cancer: a large section mapping study of entire prostatectomy specimens from 125 patients , 2016, BMC Cancer.

[4]  P. Couvreur,et al.  Knocking Down TMPRSS2-ERG Fusion Oncogene by siRNA Could be an Alternative Treatment to Flutamide , 2016, Molecular therapy. Nucleic acids.

[5]  S. Serrano,et al.  Association of ERG and TMPRSS2‐ERG with grade, stage, and prognosis of prostate cancer is dependent on their expression levels , 2015, The Prostate.

[6]  P. Couvreur,et al.  Antineoplastic Effects of siRNA against TMPRSS2-ERG Junction Oncogene in Prostate Cancer , 2015, PloS one.

[7]  S. Terry,et al.  Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer , 2015, Cancer.

[8]  T. Visakorpi,et al.  Prevalence and prognostic significance of TMPRSS2‐ERG gene fusion in lymph node positive prostate cancers , 2014, The Prostate.

[9]  J. Oxley,et al.  Quantitative analysis of ERG expression and its splice isoforms in formalin-fixed, paraffin-embedded prostate cancer samples: association with seminal vesicle invasion and biochemical recurrence. , 2014, American journal of clinical pathology.

[10]  J. Suh,et al.  Effect of Gleason scores of lymph node metastases on prognosis of patients with prostate cancer. , 2014, International journal of clinical and experimental pathology.

[11]  P. Stattin,et al.  TMPRSS2-ERG Expression Predicts Prostate Cancer Survival and Associates with Stromal Biomarkers , 2014, PloS one.

[12]  A. Sood,et al.  Highly Specific Targeting of the TMPRSS2/ERG Fusion Gene Using Liposomal Nanovectors , 2012, Clinical Cancer Research.

[13]  B. Czerniak,et al.  The relationship of TMPRSS2-ERG gene fusion between primary and metastatic prostate cancers. , 2012, Human pathology.

[14]  H. Schlüter,et al.  ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy , 2011, Clinical Cancer Research.

[15]  G. Nesi,et al.  Clinical importance of lymph node density in predicting outcome of prostate cancer patients. , 2011, The Journal of surgical research.

[16]  B. Wiese,et al.  Androgen receptors are differentially expressed in Gleason patterns of prostate cancer and down‐regulated in matched lymph node metastases , 2011, The Prostate.

[17]  C. Magi-Galluzzi,et al.  Use of TMPRSS2-ERG gene rearrangement and quantitative ERG expression to predict clinical recurrence after radical prostatectomy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Rubin,et al.  Testing mutual exclusivity of ETS rearranged prostate cancer , 2010, Laboratory Investigation.

[19]  F. Deng,et al.  Detection of TMPRSS2 Gene Deletions and Translocations in Carcinoma, Intraepithelial Neoplasia, and Normal Epithelium of the Prostate by Direct Fluorescence In Situ Hybridization , 2010, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[20]  S-H Tan,et al.  ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification , 2010, Prostate Cancer and Prostatic Diseases.

[21]  M. Rubin,et al.  ERG rearrangement metastasis patterns in locally advanced prostate cancer. , 2010, Urology.

[22]  M. Rubin,et al.  TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. , 2007, Urology.

[23]  S. Dhanasekaran,et al.  Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer , 2007, Nature.

[24]  Debashis Ghosh,et al.  Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer , 2007, Modern Pathology.

[25]  F. Wawroschek,et al.  Sentinel lymph node dissection for prostate cancer: experience with more than 1,000 patients. , 2007, The Journal of urology.

[26]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[27]  B. Wullich,et al.  Lymph node positive prostate cancer: long-term survival data after radical prostatectomy. , 2004, The Journal of urology.

[28]  F. Burkhard,et al.  Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? , 2003, The Journal of urology.

[29]  T. Stamey,et al.  Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. , 2002, Urology.

[30]  K. Klose,et al.  [Venous occlusive disease of the liver--a rare pregnancy complication]. , 1990, Der Internist.

[31]  P. Scardino,et al.  Prognostic significance of lymph nodal metastases in prostate cancer. , 1989, The Journal of urology.

[32]  G. Sauter,et al.  Marked heterogeneity of ERG expression in large primary prostate cancers , 2013, Modern Pathology.

[33]  S. Dhanasekaran,et al.  ETS rearrangements and prostate cancer initiation , 2009, Nature.

[34]  D. Bostwick,et al.  Risk of prostate carcinoma death in patients with lymph node metastasis , 2001, Cancer.

[35]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.